Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q7KZI7

UPID:
MARK2_HUMAN

ALTERNATIVE NAMES:
ELKL motif kinase 1; MAP/microtubule affinity-regulating kinase 2; PAR1 homolog; PAR1 homolog b

ALTERNATIVE UPACC:
Q7KZI7; Q15449; Q15524; Q5XGA3; Q68A18; Q96HB3; Q96RG0

BACKGROUND:
The protein Serine/threonine-protein kinase MARK2, known by alternative names such as ELKL motif kinase 1, is integral to regulating cell polarity, microtubule dynamics, and neuronal migration. It achieves this through phosphorylation of various proteins including MAPT/TAU and HDAC7, affecting their interaction with microtubules and cellular localization. MARK2's activity is also essential in the Wnt signaling pathway and in determining epithelial cell fate.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Serine/threonine-protein kinase MARK2 holds promise for unveiling novel therapeutic avenues.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.